135 related articles for article (PubMed ID: 31268309)
41. Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3).
Penning TM; Burczynski ME; Jez JM; Lin HK; Ma H; Moore M; Ratnam K; Palackal N
Mol Cell Endocrinol; 2001 Jan; 171(1-2):137-49. PubMed ID: 11165022
[TBL] [Abstract][Full Text] [Related]
42. Preclinical Pharmacokinetics, Tissue Distribution and Primary Safety Evaluation of a Novel Curcumin Analogue H10 Suspension, a Potential 17β Hydroxysteroid Dehydrogenase Type 3 Inhibitor.
Xiao L; Bei Y; Li J; Chen M; Zhang Y; Xiang Q
Chem Pharm Bull (Tokyo); 2021 Jan; 69(1):52-58. PubMed ID: 33087639
[TBL] [Abstract][Full Text] [Related]
43. Effects of phthalates on 3β-hydroxysteroid dehydrogenase and 17β-hydroxysteroid dehydrogenase 3 activities in human and rat testes.
Yuan K; Zhao B; Li XW; Hu GX; Su Y; Chu Y; Akingbemi BT; Lian QQ; Ge RS
Chem Biol Interact; 2012 Feb; 195(3):180-8. PubMed ID: 22214983
[TBL] [Abstract][Full Text] [Related]
44. Synthesis of a dansyl-labeled inhibitor of 17β-hydroxysteroid dehydrogenase type 3 for optical imaging.
Kenmogne LC; Maltais R; Poirier D
Bioorg Med Chem Lett; 2016 May; 26(9):2179-83. PubMed ID: 27025340
[TBL] [Abstract][Full Text] [Related]
45. Synthesis and optimization of a new family of type 3 17 beta-hydroxysteroid dehydrogenase inhibitors by parallel liquid-phase chemistry.
Maltais R; Luu-The V; Poirier D
J Med Chem; 2002 Jan; 45(3):640-53. PubMed ID: 11806715
[TBL] [Abstract][Full Text] [Related]
46. Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Fink BE; Gavai AV; Tokarski JS; Goyal B; Misra R; Xiao HY; Kimball SD; Han WC; Norris D; Spires TE; You D; Gottardis MM; Lorenzi MV; Vite GD
Bioorg Med Chem Lett; 2006 Mar; 16(6):1532-6. PubMed ID: 16386902
[TBL] [Abstract][Full Text] [Related]
47. Identification of chemically diverse, novel inhibitors of 17β-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening.
Schuster D; Kowalik D; Kirchmair J; Laggner C; Markt P; Aebischer-Gumy C; Ströhle F; Möller G; Wolber G; Wilckens T; Langer T; Odermatt A; Adamski J
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):148-61. PubMed ID: 21300150
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of type 2 17beta-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-ring: structure-activity relationships.
Bydal P; Auger S; Poirier D
Steroids; 2004 May; 69(5):325-42. PubMed ID: 15219411
[TBL] [Abstract][Full Text] [Related]
49. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
[TBL] [Abstract][Full Text] [Related]
50. Identification of steroidal derivatives inhibiting the transformations of allopregnanolone and estradiol by 17β-hydroxysteroid dehydrogenase type 10.
Boutin S; Roy J; Maltais R; Alata W; Calon F; Poirier D
Bioorg Med Chem Lett; 2018 Dec; 28(22):3554-3559. PubMed ID: 30297283
[TBL] [Abstract][Full Text] [Related]
51. The (+)- and (-)-gossypols potently inhibit both 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase 3 in human and rat testes.
Hu GX; Zhou HY; Li XW; Chen BB; Xiao YC; Lian QQ; Liang G; Kim HH; Zheng ZQ; Hardy DO; Ge RS
J Steroid Biochem Mol Biol; 2009 May; 115(1-2):14-9. PubMed ID: 19429456
[TBL] [Abstract][Full Text] [Related]
52. Inhibitors of human and rat testes microsomal 17beta-hydroxysteroid dehydrogenase (17beta-HSD) as potential agents for prostatic cancer.
Le Lain R; Nicholls PJ; Smith HJ; Maharlouie FH
J Enzyme Inhib; 2001 Jan; 16(1):35-45. PubMed ID: 11496833
[TBL] [Abstract][Full Text] [Related]
53. Demethoxylation of curcumin enhances its inhibition on human and rat 17β-hydroxysteroid dehydrogenase 3: QSAR structure-activity relationship and in silico docking analysis.
Ji Z; Sang J; Wang H; Xia M; Hao T; Chen L; Lu H; Wang S; Yao M; Li L; Ge RS
Food Chem Toxicol; 2024 Apr; 186():114489. PubMed ID: 38360388
[TBL] [Abstract][Full Text] [Related]
54. Coumarins as novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for potential treatment of prostate cancer.
Harada K; Kubo H; Tomigahara Y; Nishioka K; Takahashi J; Momose M; Inoue S; Kojima A
Bioorg Med Chem Lett; 2010 Jan; 20(1):272-5. PubMed ID: 19954971
[TBL] [Abstract][Full Text] [Related]
55. 17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development.
Marchais-Oberwinkler S; Henn C; Möller G; Klein T; Negri M; Oster A; Spadaro A; Werth R; Wetzel M; Xu K; Frotscher M; Hartmann RW; Adamski J
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):66-82. PubMed ID: 21193039
[TBL] [Abstract][Full Text] [Related]
56. Overview of a rational approach to design type I 17beta-hydroxysteroid dehydrogenase inhibitors without estrogenic activity: chemical synthesis and biological evaluation.
Tremblay MR; Poirier D
J Steroid Biochem Mol Biol; 1998 Aug; 66(4):179-91. PubMed ID: 9744515
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of 17beta-hydroxysteroid oxidoreductase by flavonoids in breast and prostate cancer cells.
Mäkelä S; Poutanen M; Kostian ML; Lehtimäki N; Strauss L; Santti R; Vihko R
Proc Soc Exp Biol Med; 1998 Mar; 217(3):310-6. PubMed ID: 9492340
[TBL] [Abstract][Full Text] [Related]
58. Aromatase and 17beta-hydroxysteroid dehydrogenase inhibition by flavonoids.
Le Bail JC; Laroche T; Marre-Fournier F; Habrioux G
Cancer Lett; 1998 Nov; 133(1):101-6. PubMed ID: 9929167
[TBL] [Abstract][Full Text] [Related]
59. Improved synthesis of EM-1745, preparation of its C17-ketone analogue and comparison of their inhibitory potency on 17beta-hydroxysteroid dehydrogenase type 1.
Bérubé M; Poirier D
J Enzyme Inhib Med Chem; 2009 Jun; 24(3):832-43. PubMed ID: 19003559
[TBL] [Abstract][Full Text] [Related]
60. Design, synthesis and in vitro evaluation of 4-androstene-3,17-dione/adenosine hybrid compounds as bisubstrate inhibitors of type 3 17beta-hydroxysteroid dehydrogenase.
Bérubé M; Laplante Y; Poirier D
Med Chem; 2006 Jul; 2(4):329-47. PubMed ID: 16848745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
